ArticleAmerican journal of cancer research2025
A predictive model based on BRCA1/2, POLE, TP53, and MSH6 mutations for immunotherapy response in advanced endometrial cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate clinical, molecular, and immunological predictors of response to immunotherapy among patients with advanced endometrial cancer and to develop a combined biomarker model for predicting treatment outcomes.
methodsThis retrospective case-control study included 590 advanced endometrial cancer patients treated at the Affiliated Hospital of Hebei University of Engineering between December 2024 and May 2025. Eligible women underwent total hysterectomy, pelvic lymph node dissection, and received immune checkpoint inhibitors alongside standard chemotherapy. Patients were stratified into good and poor response groups based on 1-year post-treatment prognosis and response evaluation criteria in solid tumors. Baseline blood biomarkers, gene mutation status (breast cancer gene [BRCA] 1, BRCA2, DNA polymerase epsilon, tumor protein p53 [TP53], mutS homolog 6), and immunophenoscore (IPS) were assessed. Logistic regression and receiver operating characteristic (ROC) analyses were performed. A random forest model was constructed for combined biomarker prediction.
resultsNo significant differences in baseline demographic or clinical characteristics were found between response groups. Good responders had significantly lower baseline levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), neutrophil-lymphocyte ratio (NLR), cancer antigen 125 (CA125), and IPS, and higher frequencies of gene mutations. Multivariate regression identified elevated CRP, IL-6, TNF-α, NLR, CA125, and IPS as independent predictors of poor response; BRCA2 and TP53 mutations were independently associated with favorable outcomes. The combined biomarker model achieved an area under the ROC curve of 0.812, demonstrating strong predictive accuracy.
conclusionInflammatory and tumor biomarkers, IPS, and specific gene mutations are independently associated with immunotherapy response in advanced endometrial cancer. A combined biomarker model may enhance the prediction of treatment outcomes and guide individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.